- Home
- OZ vs RCEL Comparison
OZ vs RCEL Comparison
Compare OZ & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- RCEL
- Stock Information
- Founded
- OZ 2020
- RCEL N/A
- Country
- OZ United States
- RCEL United States
- Employees
- OZ N/A
- RCEL N/A
- Industry
- OZ
- RCEL Medical/Dental Instruments
- Sector
- OZ
- RCEL Health Care
- Exchange
- OZ Nasdaq
- RCEL Nasdaq
- Market Cap
- OZ 236.3M
- RCEL 240.6M
- IPO Year
- OZ N/A
- RCEL N/A
- Fundamental
- Price
- OZ $63.75
- RCEL $6.97
- Analyst Decision
- OZ
- RCEL Strong Buy
- Analyst Count
- OZ 0
- RCEL 4
- Target Price
- OZ N/A
- RCEL $17.25
- AVG Volume (30 Days)
- OZ 6.0K
- RCEL 197.1K
- Earning Date
- OZ 01-01-0001
- RCEL 05-08-2025
- Dividend Yield
- OZ N/A
- RCEL N/A
- EPS Growth
- OZ N/A
- RCEL N/A
- EPS
- OZ N/A
- RCEL N/A
- Revenue
- OZ $2,675,000.00
- RCEL $71,661,000.00
- Revenue This Year
- OZ N/A
- RCEL $62.33
- Revenue Next Year
- OZ N/A
- RCEL $30.59
- P/E Ratio
- OZ N/A
- RCEL N/A
- Revenue Growth
- OZ 18.68
- RCEL 41.35
- 52 Week Low
- OZ $56.77
- RCEL $6.90
- 52 Week High
- OZ $82.89
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- OZ 53.29
- RCEL 28.06
- Support Level
- OZ $62.95
- RCEL $9.50
- Resistance Level
- OZ $64.50
- RCEL $9.85
- Average True Range (ATR)
- OZ 0.96
- RCEL 0.53
- MACD
- OZ 0.31
- RCEL -0.20
- Stochastic Oscillator
- OZ 78.43
- RCEL 10.03
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.